<DOC>
	<DOCNO>NCT02908685</DOCNO>
	<brief_summary>Multi-center , randomize , double-blind , placebo-controlled , Phase II study ass safety , tolerability , pharmacokinetic , pharmacodynamics , efficacy RO7034067 adult pediatric patient Type 2 Type 3 spinal muscular atrophy ( SMA ) . The study consist two part , exploratory dose find part ( Part 1 ) RO7034067 12-weeks confirmatory part ( Part 2 ) RO7034067 24-months .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Efficacy RO7034067 Type 2 3 Spinal Muscular Atrophy Participants ( Sunfish )</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>For Part 1 : Type 2 3 SMA ambulant nonambulant . For Part 2 : Type 2 3 SMA nonambulant Confirmed diagnosis 5qautosomal recessive SMA For Part 2 : 1 ) revise upper limb module ( RULM ) entry item A great equal [ &gt; = ] 2 ; 2 ) ability sit independently assess item 9 motor function measure ( MFM ) Negative blood pregnancy test screening agreement comply measure prevent pregnancy restriction sperm donation Concomitant previous participation investigational drug device study within 90 day prior screen , 5 halflives drug , whichever longer Concomitant previous participation time Survival motor neuron ( SMN ) 2 target antisense oligonucleotide , SMN2 splice modifier gene therapy study Any history cell therapy Hospitalization pulmonary event within last 2 month plan time screen Surgery scoliosis hip fixation one year precede screening plan within next 18 month Unstable gastrointestinal , renal , hepatic , endocrine , cardiovascular system disease consider clinically significant Investigator Presence clinically significant electrocardiogram ( ECG ) abnormality study drug administration average triplicate measurement cardiovascular disease indicate safety risk participant determine Investigator Any major illness within one month screen examination febrile illness within one week prior screen first dose administration Any inhibitor cytochrome P450 ( CYP ) 3A4 and/or Organic Cation Transporter 2 ( OCT2 ) multidrug toxin extrusion ( MATE ) substrates take within 2 week and/or inducer CYP3A4 take within 4 week ( within 5times elimination halflife , whichever long ) prior dose participant take nutrient know modulate CYP3A activity Recently initiate treatment ( within less [ &lt; ] 6 month prior randomization ) oral salbutamol another beta 2adrenergic agonist take orally Any prior use chloroquine , hydroxychloroquine , retigabin , vigabatrin thioridazine , allow Ascertained presumptive hypersensitivity ( e.g. , anaphylactic reaction ) RO7034067 constituent formulation Recent history ( less one year ) ophthalmological disease</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>